It looks like you're offline.
Open Library logo
additional options menu

MARC record from Internet Archive

LEADER: 04807cam 2200889Mi 4500
001 ocn228064162
003 OCoLC
005 20200517203502.0
008 950316s1995 dcu ob 000 0 eng
006 m o d
007 cr cn|||||||||
040 $aNz$beng$erda$epn$cUV0$dOCLCQ$dCUSER$dE7B$dIDEBK$dOCLCQ$dCUS$dOCLCQ$dN$T$dYDXCP$dCOF$dVRA$dORU$dFVL$dOCLCQ$dDKDLA$dOCLCQ$dNLGGC$dOCLCQ$dITD$dAZK$dLOA$dOCLCQ$dOCLCO$dOCLCA$dTOA$dOCLCO$dAGLDB$dSUR$dOCLCO$dMOR$dPIFBR$dOCLCQ$dOCLCA$dU3W$dOCLCA$dBUF$dOCLCO$dOCLCF$dOCLCQ$dSTF$dWRM$dVNS$dOCLCO$dVTS$dCOCUF$dNRAMU$dINT$dVT2$dAU@$dOCLCO$dOCLCQ$dWYU$dOCLCA$dLVT$dOCLCA$dTKN$dOCLCQ$dOCLCO$dM8D$dOCLCO$dUKAHL$dOCLCA
019 $a44963643$a326717434$a647367440$a666930842$a698448128$a722262416$a728020139$a888526612$a961592371$a961647488$a962593828$a962684881
020 $a0585142386$q(electronic bk.)
020 $a9780585142388$q(electronic bk.)
020 $z0309052793
020 $z9780309052795$q(pbk.)
035 $a(OCoLC)228064162$z(OCoLC)44963643$z(OCoLC)326717434$z(OCoLC)647367440$z(OCoLC)666930842$z(OCoLC)698448128$z(OCoLC)722262416$z(OCoLC)728020139$z(OCoLC)888526612$z(OCoLC)961592371$z(OCoLC)961647488$z(OCoLC)962593828$z(OCoLC)962684881
050 4 $aRC848.H44$bR48 1995eb
060 4 $a1995 E-468
060 4 $aQV 771$bI5853r 1995
072 7 $aMED$x114000$2bisacsh
082 04 $a616.3/623061$220
245 00 $aReview of the Fialuridine (FIAU) clinical trials /$cFrederick J. Manning and Morton Swartz, editors.
264 1 $aWashington, DC :$bNational Academy Press,$c1995.
300 $a1 online resource (ix, 269 pages)
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
347 $adata file$2rda
500 $a"Committee to Review the Fialuridine (FIAU/FIAC)--Clinical Trials, Division of Health Sciences Policy, Institute of Medicine."
504 $aIncludes bibliographical references (pages 165-177).
588 0 $aPrint version record.
650 0 $aHepatitis B$xChemotherapy$xEvaluation.
650 0 $aFialuridine$xTesting.
650 0 $aFiacitabine$xTesting.
650 0 $aClinical trials$xSafety measures.
650 12 $aClinical Trials as Topic.
650 12 $aArabinofuranosyluracil$xanalogs & derivatives.
650 22 $aHepatitis B$xdrug therapy.
650 22 $aAntiviral Agents$xadverse effects.
650 22 $aArabinofuranosyluracil$xtoxicity.
650 7 $aMEDICAL$xHepatology.$2bisacsh
650 7 $aClinical trials$xSafety measures.$2fast$0(OCoLC)fst00864438
650 7 $aFiacitabine$xTesting.$2fast$0(OCoLC)fst00923546
650 7 $aFialuridine$xTesting.$2fast$0(OCoLC)fst00923548
655 0 $aElectronic books.
655 4 $aElectronic books.
700 1 $aManning, Frederick J.
700 1 $aSwartz, Morton N.
776 08 $iPrint version:$tReview of the Fialuridine (FIAU) clinical trials.$dWashington, DC : National Academy Press, 1995$w(DLC) 95068327
856 40 $3ebrary$uhttp://site.ebrary.com/id/10056943
856 40 $3EBSCOhost$uhttp://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=14063
856 40 $3MyiLibrary$uhttp://www.myilibrary.com?id=19292
856 40 $3National Academies Press$uhttp://www.nap.edu/catalog.php?record_id=4887
856 40 $3National Academies Press$uhttp://www.nap.edu/catalog/4887.html
856 40 $3National Academies Press$uhttps://www.nap.edu/catalog.php?record_id=4887
856 40 $3National Academies Press$uhttp://www.nap.edu/openbook.php?record_id=4887
856 40 $3National Academies Press$uhttps://www.nap.edu/4887
856 40 $3ProQuest Ebook Central$uhttp://public.ebookcentral.proquest.com/choice/publicfullrecord.aspx?p=3376667
856 40 $zVIEW FULL TEXT$uhttp://VH7QX3XE2P.search.serialssolutions.com/?V=1.0&L=VH7QX3XE2P&S=JCs&C=TC0000237578&T=marc&tab=BOOKS
856 4 $3EBSCOhost$uhttp://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=14063
856 40 $uhttp://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=14063$xWMS$yEBSCO Academic Comprehensive Collection$xProvider: EBSCO$xsubscribed$xeLoaderURL$xuc4$xucocn228064162
856 40 $uhttp://www.vlebooks.com/vleweb/product/openreader?id=none&isbn=9780309573443
938 $aAskews and Holts Library Services$bASKH$nAH36566969
938 $aebrary$bEBRY$nebr10056943
938 $aEBSCOhost$bEBSC$n14063
938 $aYBP Library Services$bYANK$n2308999
938 $aYBP Library Services$bYANK$n6012450
029 0 $aNZ1$b11927653
029 1 $aAU@$b000051522268
029 1 $aAU@$b000053231564
029 1 $aDEBBG$bBV043133422
029 1 $aDEBSZ$b422567698
029 1 $aGBVCP$b802568580
994 $aZ0$bP4A
948 $hNO HOLDINGS IN P4A - 1418 OTHER HOLDINGS